Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK

被引：0
|
作者：
Mughal, F. [1 ]
Barker, J. [2 ]
Cawston, H. [3 ]
Damera, V. [3 ]
Bewley, A. [4 ,5 ]
Morris, J. [6 ]
Shaw, T. [7 ]
Tencer, T. [8 ]
Zhang, F. [8 ]
机构：
[1] Celgene Ltd, Uxbridge, Middx, England
[2] St Johns Inst Dermatol Kings Coll, London, England
[3] Mapi Grp, London, England
[4] Whipps Cross Univ Hosp, London, England
[5] Royal London Hosp, London, England
[6] Cogentia Healthcare Consulting, Cambridge, England
[7] Celgene Ltd, Southall, Middx, England
[8] Celgene Corp, Summit, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2016年 / 175卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of amevivetm (Alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [22] The management of moderate-to-severe chronic plaque psoriasis
    Tonini, Annalisa
    Panduri, Salvatore
    D'Erme, Angelo M.
    Papadia, Francesca
    Romaneli, Marco
    Krueger, James G.
    Chiricozzi, Andrea
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05): : 447 - 457
  • [23] MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US
    Verma, S.
    Dharmarajan, S.
    Yang, Y.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [24] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [25] COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
    Ortonne, J. P.
    Feneron, D.
    Daures, J. P.
    Ollivier, A. L.
    Thiriet, C.
    Maurel, F.
    Le Pen, C.
    VALUE IN HEALTH, 2008, 11 (06) : A617 - A617
  • [26] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [27] Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective
    Igarashi, Atsuyuki
    Igarashi, Ataru
    Graham, Christopher N.
    Gilloteau, Isabelle
    Tani, Yumiko
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 7 - 15
  • [28] COST-EFFECTIVENESS OF SEQUENCES OF BIOLOGIC TREATMENTS FOR MODERATE-TO-SEVERE PSORIASIS IN FINLAND
    Asseburg, C.
    Valgardsson, S.
    Soini, E. J.
    VALUE IN HEALTH, 2013, 16 (07) : A507 - A508
  • [29] Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis
    Sacchelli, L.
    Patrizi, A.
    Loi, C.
    Bardazzi, F.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (07) : E243 - E244
  • [30] COST-EFFECTIVENESS OF TARGETED THERAPY FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS: AN ANALYSIS BASED ON AN INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER) REPORT
    Hendrix, N.
    Endorf, D.
    Chapman, R. H.
    Loos, A.
    Liu, S.
    Kumar, V
    Linder, J. A.
    Pearson, S. D.
    Veenstra, D. L.
    VALUE IN HEALTH, 2017, 20 (05) : A158 - A158
12345